VA Disability: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Reviewed by Jonathan Teplitsky · Updated September 2026 · Informational only — not legal or medical advice; Rank and Pay is not affiliated with the VA.

Clinical Definition and Diagnostic Features of CIDP

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an acquired, immune-mediated disorder that damages the myelin sheath of peripheral nerves. The condition causes symmetric motor weakness, diminished deep tendon reflexes, and sensory disturbances such as numbness or tingling. Symptoms typically emerge in the lower extremities before progressing into the upper limbs.

Clinical confirmation requires objective electrodiagnostic testing to demonstrate peripheral demyelination. Nerve Conduction Studies (NCS) and Electromyography (EMG) identify slowed conduction velocities, prolonged distal latencies, and conduction blocks. A lumbar puncture analyzing Cerebrospinal Fluid (CSF) frequently detects elevated protein levels without an accompanying rise in white blood cells, a finding known as albuminocytologic dissociation.

Distinctions Between CIDP and Guillain-Barré Syndrome

The primary clinical difference between Chronic Inflammatory Demyelinating Polyneuropathy and Guillain-Barré Syndrome (GBS) is the progression timeline of neurological impairment. Guillain-Barré Syndrome is an acute, typically monophasic polyneuropathy that reaches peak symptom severity within about 4 weeks. In contrast, CIDP symptoms progress or relapse over a period of 8 weeks or longer.

Both disorders share similar autoimmune mechanisms that target peripheral nerve myelin. Neurologists frequently characterize CIDP as the chronic counterpart of GBS due to these shared pathological features. Medical management differs because GBS usually follows a self-limiting course, whereas CIDP requires long-term therapy for chronic or relapsing neurological deficits.

CIDP VA Rating Criteria and Peripheral Nerve Analogy

The Department of Veterans Affairs (VA) does not assign a single dedicated Diagnostic Code (DC) to Chronic Inflammatory Demyelinating Polyneuropathy. Adjudicators rate CIDP under 38 CFR § 4.124a by analogy to the specific peripheral nerves damaged by the disease. Ratings are assigned using the diagnostic code for whichever individual nerve shows motor or sensory loss on clinical examination.

Upper-extremity nerve impairment is evaluated under DC 8510 to DC 8516 for major branches such as the median, ulnar, or radial nerves. Claimants can compare these upper-limb criteria with the evaluation framework for upper radiculopathy. Lower-extremity nerve impairment is rated under DC 8520 to DC 8730 for the sciatic, peroneal, and tibial nerves, as outlined in the guide for lower radiculopathy and the general schedule for peripheral neuropathy.

Illustrative Severity Tiers for Sciatic Nerve Under DC 8520

The rating schedule does not provide a uniform percentage for all nerve conditions. The sciatic nerve under Diagnostic Code 8520 illustrates how the VA structures peripheral nerve disability tiers across different degrees of impairment.

Rating Ceilings for Neuritis and Neuralgia

Disability ratings for inflammatory nerve conditions are subject to regulatory ceilings established in 38 CFR Part 4. Under 38 CFR § 4.123, neuritis is defined by loss of reflexes, muscle atrophy, and sensory disturbance. Ratings assigned under the neuritis schedule cannot exceed the rating established for severe incomplete paralysis of the affected nerve.

Because CIDP is an inflammatory demyelinating process, adjudicators apply the neuritis criteria and its severe incomplete paralysis ceiling. A claimant cannot receive a rating for complete paralysis under neuritis provisions unless examination findings establish a distinct, separately diagnosed complete paralysis. If peripheral nerve involvement causes persistent pain without significant motor weakness or reflex loss, adjudicators apply 38 CFR § 4.124 for neuralgia, which carries a lower ceiling of moderate incomplete paralysis.

The general instructions of 38 CFR § 4.124a also limit ratings based exclusively on sensory loss. When nerve involvement is wholly sensory, the evaluation is restricted to the mild, or at most, the moderate degree. Higher disability percentages require objective motor impairment, such as documented loss of muscle strength or measurable muscle atrophy.

Bilateral Factor and Multiple Nerve Involvement

Peripheral nerve ratings in 38 CFR § 4.124a apply to unilateral involvement of an individual extremity. Because CIDP typically affects limbs symmetrically, counterpart nerves on both sides of the body are evaluated separately. When both arms or both legs are impaired, the VA combines the ratings and adds a 10 percent bilateral factor under 38 CFR § 4.26.

Combined disability percentages can be calculated using the VA disability rating calculator. When a claimant has co-existing conditions, such as diabetic neuropathy alongside CIDP, ratings are based on the total functional impairment of each affected nerve. VA regulations prohibit duplicate ratings for the same functional loss under the anti-pyramiding rule in 38 CFR § 4.14.

Ratings are determined nerve by nerve across all four limbs. If electrodiagnostic studies establish impairment in both peroneal nerves and both ulnar nerves, the adjudicator assigns four separate evaluations. Those four evaluations are then combined using the bilateral calculation rules.

Service Connection and Agent Orange Exposure Determinations

Chronic Inflammatory Demyelinating Polyneuropathy is not on the VA list of presumptive conditions associated with herbicide exposure. The official Agent Orange presumptive conditions directory does not include CIDP. A veteran cannot establish service connection on a presumptive basis for this diagnosis.

Establishing service connection for CIDP linked to military service requires direct service connection. Claimants must provide three elements: a current medical diagnosis of CIDP, documented in-service exposure or an in-service event, and a competent medical nexus opinion linking the two. Guidance on medical nexus letters is available in the medical nexus letter guide, while qualifying locations can be verified through the Agent Orange exposure guide, the 2026 Agent Orange expansion list, and the complete presumptive conditions overview.

Decisions by the Board of Veterans' Appeals (BVA) regarding CIDP and Agent Orange exposure have reached different outcomes based on the medical evidence in each file. In some published Board decisions, service connection was granted when a competent medical opinion concluded it was at least as likely as not that herbicide exposure contributed to the disease.

In other published decisions, the Board denied the claim due to the absence of scientific evidence or a persuasive nexus opinion connecting herbicide exposure to demyelinating polyneuropathy. Adjudication outcomes remain evidence-dependent and require case-by-case medical evaluation.

Proposed Neurological Rating Schedule Revisions

The Department of Veterans Affairs published a proposed rule in the Federal Register to reorganize the neurological rating schedule. Published on November 12, 2024, the notice titled Schedule for Rating Disabilities: Neurological Conditions and Convulsive Disorders (89 FR 88917, RIN 2900-AR47) proposes moving peripheral nerve ratings into a revised section. This framework would introduce updated evaluation criteria for motor, sensory, and mental impairments.

The public comment period for this proposed regulation closed on January 13, 2025. As of September 2026, the proposed rule has not been finalized by the VA and carries no effective date. Adjudicators continue to evaluate all CIDP and peripheral nerve disability claims under the existing provisions of 38 CFR § 4.124a.

Medical Evidence and Claim Documentation Standards

Adjudicating a CIDP disability claim requires objective medical records establishing the anatomical distribution and functional severity of nerve impairment. Nerve conduction studies and electromyograms provide essential baseline evidence by documenting demyelinating features across specific peripheral nerves. Longitudinal clinical treatment notes showing progressive or relapsing motor weakness over 8 or more weeks confirm the chronic character of the condition.

Compensation and Pension (C&P) examinations evaluate motor strength, deep tendon reflexes, sensory deficits, and muscle atrophy in each limb. Documenting how physical limitations affect daily activities such as standing, walking, or gripping objects assists adjudicators in assigning the correct rating tier. Information regarding effective dates and retroactive compensation can be reviewed in the VA disability back pay explainer.

Claimants preparing a claim can review their electrodiagnostic records to identify the specific peripheral nerves involved before obtaining a formal medical nexus opinion.

This page is informational only and is not legal or medical advice. Rank and Pay is not affiliated with the Department of Veterans Affairs. Rating criteria are summarized from 38 CFR Part 4; for your specific claim, consult the VA, an accredited Veterans Service Officer (VSO), or an accredited attorney.